Contents
On this page
- Scope of the four principal instruments
- Authorship and contributorship
- Duplicate publication, text recycling and plagiarism
- Additional requirements for sponsored research under GPP
- Reporting guidelines as instruments of publication ethics
- Research conduct, consent and data protection as prior requirements
- Frequency of publication-ethics failures
- Composition of the disclosure block
- Summary and further guidance
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Publication · Publication ethics
Publication Ethics: Identifying the Instrument That Governs Each Question
Publication ethics is governed not by a single rulebook but by four or five separate instruments, written by different bodies for different problems. Much of the confusion that authors encounter arises from asking one instrument a question it was not written to answer. This article classifies the common questions and identifies the document that resolves each one.
Authors facing a specific problem — a co-author who wrote nothing, a congress abstract about to become a full paper, or a sponsor seeking to approve the manuscript — commonly search for “publication ethics” and encounter general exhortation. Such a problem requires a routing decision: which body issued the governing rule, what precisely that rule states, and what it deliberately leaves to the journal. ICMJE, COPE, GPP and the EQUATOR reporting guidelines overlap at their margins, but each governs a distinct core. The first step is therefore to identify the instrument to which a question belongs.
Learning objectives
- Which of the four main instruments — ICMJE, COPE, GPP, and the EQUATOR reporting guidelines — governs a given question
- The four ICMJE authorship criteria and why all four must be met by every named author
- Where the boundary falls between acceptable secondary publication, text recycling and duplicate publication
- The circumstances in which GPP applies to a manuscript
- The frequency of authorship and duplication failures in the literature, as reported in published audits
- The composition of a disclosure block that anticipates the questions an editor would otherwise raise
Common misconceptions
- “Publication ethics is one set of rules.” It comprises at least four instruments, with different scopes and different issuing bodies. ICMJE governs authorship and overlapping publication; COPE governs how journals and editors handle allegations; GPP governs company-sponsored research; EQUATOR guidelines govern how a given design is reported.
- “Anyone who contributed should be an author.” The ICMJE criteria are cumulative rather than alternative. A contributor who collected data but did not help draft or revise the work, and will not approve the final version, is acknowledged rather than listed.
- “Reusing one’s own words cannot constitute plagiarism.” Self-reuse is a recognised and contested category with its own guidance (COPE’s text recycling guidelines and Moskovitz’s work in Science and Engineering Ethics), and it is handled separately from duplicate publication of data.
- “Ethics problems are rare and occur only in the work of others.” Wislar and colleagues found inappropriate authorship in 21% of articles in six leading general medical journals in 2008, and Fang and colleagues found 67.4% of 2,047 retractions in PNAS were for misconduct rather than error.
- “A reporting guideline is a formatting chore, not an ethics instrument.” Incomplete reporting of a trial’s outcomes and harms misleads readers irrespective of the author’s intentions, which is why CONSORT and related guidelines sit alongside the conduct codes rather than below them.
Scope of the four principal instruments
The documents that constitute publication ethics were written at different times by different bodies, each responding to a problem that the others had not resolved. Distinguishing between them saves most of the time otherwise spent on these questions.
The ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals is the oldest and broadest. It began in 1978 as the Uniform Requirements for Manuscripts Submitted to Biomedical Journals and has been revised repeatedly since 1. It is the document that defines authorship, sets out what counts as overlapping or duplicate publication, requires prospective trial registration and, since its 2017 revision, requires data sharing statements 1,3. A question of whether a given action is permitted is usually answered by ICMJE.
COPE’s Core Practices is written for a different reader. It describes what a journal must have in place — policies on authorship, complaints, misconduct allegations, corrections and retractions — and supplies the flowcharts an editor follows when something goes wrong 4. Authors consult COPE mainly to determine what will happen to them and to read its specific guidance, such as the text recycling guidelines 2. A question of what the journal will do next is answered by COPE.
Good Publication Practice, now in its 2022 edition from DeTora and colleagues in Annals of Internal Medicine, covers company-sponsored biomedical research specifically 7. It exists because the sponsor relationship raises questions (who holds the data, who may veto a publication and how professional writing support is disclosed) that ICMJE addresses only in principle. If a commercial sponsor is involved at any stage, GPP applies in addition to ICMJE, not instead of it.
The reporting guidelines (CONSORT for parallel-group randomised trials, PRISMA for systematic reviews, STROBE for observational studies, CARE for case reports and the remainder of the EQUATOR collection) answer a narrower question than any of the above: given a particular study design, what must the paper state? They are not optional presentation advice. A trial report that omits its primary outcome or its harms is misleading regardless of intent.
Problems and the instruments that govern them
| If your problem is… | The instrument | Issued by | What it will not settle |
|---|---|---|---|
| Who qualifies as an author, and who is acknowledged | ICMJE Recommendations — four cumulative authorship criteria | International Committee of Medical Journal Editors | Disputes about the relative order of authors, which is a matter of local convention |
| Whether a second paper from the same data is permissible | ICMJE Recommendations — overlapping and secondary publication | ICMJE | Whether a specific journal will accept it; the editor should be consulted in advance |
| Reuse of an author’s own methods text in a new paper | Text recycling guidelines | COPE | The acceptable extent of reuse, on which the sources disagree |
| What happens after an allegation is made against a paper | Core Practices and the COPE flowcharts | COPE | Timing; journal practice varies widely |
| A commercial sponsor’s role, veto rights, or writing support | GPP 2022 | ISMPP, published in Annals of Internal Medicine | Journal-specific disclosure wording |
| What a paper about this design must state | CONSORT, PRISMA, STROBE, CARE and the EQUATOR collection | The respective guideline groups | Whether the study was worth doing |
| Consent, approval, and research involving humans | Declaration of Helsinki; CIOMS guidelines | World Medical Association; CIOMS | Whether data may lawfully leave the institution |
| Whether participant data may lawfully be shared | GDPR and national implementations | European Union and national regulators | Much of it; the research exemptions are unsettled |
Compiled from the instruments named, as cited in the reference list below. Scope boundaries are our reading of each document’s stated remit, not a formal mapping endorsed by the issuing bodies.
Authorship and contributorship
Authorship is the single most common source of publication-ethics disputes, and the rule is short enough to quote. The ICMJE sets four criteria, and an author must meet all four: substantial contribution to conception or design, or to acquisition, analysis or interpretation of data; drafting or critically revising the work; approval of the final version; and agreement to be accountable for the work’s integrity 1,3. A contributor who meets the first criterion but not the others should be acknowledged, not listed.
Two failures result from disregarding the cumulative structure. Honorary or guest authorship adds the name of someone who did not do the work, such as a department head or a senior collaborator. Ghost authorship omits someone who did contribute, most often a professional writer. Wislar and colleagues, in BMJ, surveyed six high-impact general medical journals and found inappropriate authorship in 21% of articles in 2008, down from 29.1% in 1996, an improvement but not a resolution of the problem. Ross and colleagues, in JAMA, documented the mechanism in detail using internal documents released in the rofecoxib litigation, and Hill and colleagues did the same for the ADVANTAGE trial in Annals of Internal Medicine 27,32. Gotzsche and colleagues, writing in PLoS Medicine, set out what the field should do about ghostwriting specifically, and the professional medical writing bodies, through Jacobs and Wager’s European Medical Writers Association (EMWA) guidelines and the American Medical Writers Association (AMWA) position statement from Hamilton and Royer, now require named disclosure rather than silence 26,36,40.
The constructive response is a contributorship statement, which names what each person did rather than asserting that each qualifies. Such a statement is harder to falsify and easier to verify. For the full criteria and their application to a disputed author list, see using the ICMJE Recommendations for ethical guidance, and for the general principles behind them, the ethics of scientific communication in biomedicine.
Duplicate publication, text recycling and plagiarism
Three different offences are commonly described as “plagiarism”, and they have different rules, detection methods and consequences. Distinguishing them is the first step in answering a question about any of them.
Duplicate or redundant publication is the publication of the same data twice without disclosure. It is a problem of data integrity rather than of writing, because the same participants are counted twice in any pooled analysis of the literature 38,44. Von Elm and colleagues, in JAMA, examined the articles used in 141 anaesthesia and analgesia systematic reviews and found that the authors of 56 of them (40%) had identified duplicate publications 38. Tramer and colleagues had already shown in BMJ the effect that this has on a result.
Text recycling is the reuse of an author’s own prose, typically in methods sections, without reuse of the data. COPE has issued specific guidelines on it, and the scholarly position remains unsettled: Moskovitz, in Science and Engineering Ethics, argues that much of what is condemned is both harmless and unavoidable, whereas Roig’s guide for the US Office of Research Integrity treats it more strictly 2,9,14. Where the instruments disagree, the journal’s own policy decides.
Plagiarism in the strict sense is the use of another person’s words or ideas as one’s own. Zhang, in Learned Publishing, described how similarity detection operates at journals in practice, and Das and Panjabi, in Perspectives in Clinical Research, explained why it particularly affects medical writers 19,21. For detailed treatment of all three, see duplicate publication, identifying multiple publication and the consequences of plagiarism. A similarity report obtained before an editor runs one is available through a plagiarism check.
Additional requirements for sponsored research under GPP
GPP applies when a company has funded, designed, conducted or supplied material for the research being published, which includes a substantial amount of academic work that authors do not regard as industry research. It adds requirements that ICMJE does not impose: a written agreement between sponsor and authors settled before drafting begins, a publication plan that includes studies with unfavourable results, disclosure of professional writing support by name and funder, and a rule that authors retain the final decision to submit 7,15,23.
The lineage is relevant because the current edition is the fourth. Wager, Field and Grossman published the first GPP in Current Medical Research and Opinion in 2003; Graf and colleagues published GPP2 in BMJ in 2009; Battisti and colleagues published GPP3 in Annals of Internal Medicine in 2015; DeTora and colleagues published GPP 2022 in the same journal 7,15,23,41. Each revision widened the scope, and a sponsor still working to GPP2 is following a document two editions out of date.
For practical application, four further pages provide more detail: using GPP for ethical guidance, how GPP evolved and why each revision happened, what has changed in GPP recently, and worked GPP cases.
Reporting guidelines as instruments of publication ethics
Reporting guidelines are often regarded as a matter of formatting, which is a misconception. Schulz, Altman and Moher’s CONSORT 2010 statement in Annals of Internal Medicine, Moher and colleagues’ PRISMA statement in PLoS Medicine, von Elm and colleagues’ STROBE statement in BMJ and Gagnier and colleagues’ CARE guidelines each specify what a reader needs in order to judge whether the study’s conclusion follows from its data 17,20,25,34. Omitting the allocation method, the pre-specified primary outcome or the harms is not a presentational lapse; it changes what the paper appears to show.
Which guideline applies is determined by design, not by subject. Our reporting guidelines page maps design to checklist, the GPP reporting standards reference covers what GPP itself requires, and writing a case report works through CARE specifically.
Research conduct, consent and data protection as prior requirements
Publication ethics inherits decisions made long before a manuscript exists. The World Medical Association’s Declaration of Helsinki, republished in JAMA, and the Council for International Organizations of Medical Sciences’ international ethical guidelines govern the conduct of research involving humans 13,16. A journal will request the name of the approving committee and the consent arrangements, and careful writing cannot remedy a study that lacked them.
Data protection has become a significant current constraint on the data sharing that ICMJE now requires. Chassang, in ecancermedicalscience, and Rumbold and Pierscionek, in the Journal of Medical Internet Research, set out how the EU General Data Protection Regulation bears on research; Vlahou and colleagues, in Hypertension, argued that research ethics and data protection law are not yet harmonised; and Christofidou and colleagues, in Frontiers in Medicine, examined the consent models in use and whether data altruism offers a route through 5,8,11,12. In summary, the obligation to share and the obligation to protect are not fully reconciled, and a data sharing statement must describe a mechanism that is lawful in the relevant jurisdiction rather than an aspiration.
Frequency of publication-ethics failures
Two sets of figures merit attention, because they indicate the extent to which these concerns are practical rather than theoretical. Fang, Steen and Casadevall, in the Proceedings of the National Academy of Sciences of the USA, classified 2,047 retracted biomedical and life-science articles indexed in PubMed as of 3 May 2012 18. Misconduct accounted for 67.4% of retractions — 43.4% fraud or suspected fraud, 14.2% duplicate publication and 9.8% plagiarism — against 21.3% for error. They also found that the share of published articles retracted for fraud or suspected fraud had risen roughly tenfold since 1975, a rise not explained by growth in publication volume alone.
On the authorship side, the figure from Wislar and colleagues of 21% of articles with inappropriate authorship in six leading journals in 2008 is the more concerning, precisely because those journals have explicit policies. The literature does not establish how much of this is deliberate. Fanelli’s meta-analysis of survey data in PLoS ONE and Titus, Wells and Rhoades’ work in Nature both suggest that self-reported fabrication is rarer than observed problems, which is consistent with most of the 21% reflecting inattention to a rule that authors had not read 24,31.
Classification of 2,047 retracted biomedical and life-science articles indexed in PubMed as of 3 May 2012; error accounted for 21.3%. Source: Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. Proceedings of the National Academy of Sciences of the USA.
Composition of the disclosure block
Despite the breadth of the material above, publication ethics becomes concrete for an author in a short block of text near the end of the manuscript: funding, the sponsor’s role, writing support, competing interests and data availability. Editors read this block, and an insufficiently detailed one generates queries. The two versions below describe the same study.
The same study’s disclosure block, written twice
Generates editorial queries
This study was supported by XYZ Pharma. The authors thank Jane Smith for editorial assistance. The authors have no conflicts of interest to declare. Data are available on request.
“Supported by” says nothing about the sponsor’s role. Design, data custody, analysis and the decision to submit are all left unstated, which is precisely what GPP asks to be stated.
“Editorial assistance” conceals a professional writer. It gives no employer, funder or scope, and it is the wording that the ghostwriting literature identifies as problematic.
“No conflicts” is asserted collectively. ICMJE expects a per-author declaration, and at least two authors here are sponsor employees.
“Available on request” is not a mechanism. ICMJE has required a data sharing statement since 1 July 2018, and a statement with no route, timeframe or conditions does not satisfy the requirement.
Answers them in advance
This study was funded by XYZ Pharma, which designed the trial with the academic steering committee, held the database and conducted the primary analysis. All authors had access to the full dataset and the decision to submit rested with the authors. Medical writing support was provided by Jane Smith, PhD, of ABC Medical Communications, funded by XYZ Pharma; her role was limited to drafting from an author-approved outline and incorporating author revisions, she does not meet ICMJE authorship criteria, and she is named with her consent. A.B. and C.D. are employees of XYZ Pharma. E.F. has received consultancy fees from XYZ Pharma and two other manufacturers within the past 36 months. G.H. declares no competing interests. De-identified individual participant data underlying these results will be available to qualified researchers from 12 months after publication through the sponsor’s data-sharing portal, subject to a data access agreement.
The sponsor’s role is itemised, and author control of submission is stated explicitly.
The writer is named with employer, funder, scope and the reason she is not an author, which distinguishes declared writing support from ghost authorship.
Each author’s interests are declared separately, including employment, with a stated lookback period.
Data availability names what, to whom, from when, by what route and on what condition.
The second version is four sentences longer and pre-empts every routine query an editor would raise about this block. None of it required a decision to be changed, only that decisions already taken be documented. That constitutes most of what compliance with these instruments involves in practice.
Summary and further guidance
For a specific question, the table below indicates the relevant page. Authors seeking to establish a habit rather than to solve a single problem should read the ICMJE Recommendations in full once, since the document is shorter than its reputation suggests, and then the reporting guideline that matches the design they use most often. Those two documents cover the majority of journal queries.
Where a question concerns process rather than rules (who signs what, in which order and before submission), our publication journey checklists work through the sequence, and medical writing and regulatory writing describe the circumstances in which Pubrica undertakes the drafting work directly.
Routing by question to the page that answers it
| Your question | Where it is answered |
|---|---|
| Who counts as an author, and how should the contributorship statement be written? | Using the ICMJE Recommendations for ethical guidance |
| What are the underlying principles, as distinct from the rules? | Principles and ethics of scientific communication in biomedicine |
| Does a second paper constitute duplicate publication? | Duplicate publication |
| How would an editor or reviewer detect overlap? | Identification of multiple publication |
| What happens if plagiarism is identified? | Consequences of plagiarism in scientific writing |
| What additional requirements apply to company-funded work? | Using GPP for ethical guidance |
| What is the rationale for the provisions of GPP, and what changed between editions? | Evolution of GPP · Recent trends in GPP |
| What compliance looks like in a worked scenario | Worked GPP examples · GPP reporting standards applied to a scenario |
| What must a paper of a given design report? | Reporting standards of GPP · Reporting guidelines by design |
Internal routing. Each target page carries its own verified reference list.
Key points
Key points
Publication ethics comprises four instruments rather than one, and a question is most efficiently answered by identifying the body that issued the relevant rule. ICMJE governs authorship, overlapping publication, registration and data sharing statements. COPE governs the actions a journal takes when a problem arises, and issues the specific guidance on text recycling. GPP adds requirements concerning the sponsor relationship whenever a company is involved. The EQUATOR reporting guidelines govern what a paper of a given design must state. Where these documents diverge — most visibly on the acceptable extent of self-reuse — the journal’s own policy is decisive, and authors are advised to consult the journal before submission rather than after.
Application to your study
Application to your study
- Identify the governing instrument before seeking an answer. Questions of authorship and overlap are addressed by ICMJE; questions of process by COPE; questions concerning sponsors by GPP 2022; and questions of what must be reported by the reporting guideline for the study design.
- Assess every author against all four ICMJE criteria, in writing. A contributor who does not meet any one of them should be listed in the acknowledgements, with a stated contribution.
- Draft the contributorship statement before the author list is finalised, not afterwards. A description of each person’s contribution makes an unjustifiable authorship claim immediately apparent.
- List every prior public appearance of these data — congress abstracts, posters, preprints, registry results postings — and disclose them in the cover letter without waiting for an editorial request.
- Where the work received any commercial funding, consult GPP 2022 rather than GPP2. Confirm there is a written sponsor–author agreement, and that it leaves the decision to submit with the authors.
- Compile the disclosure block as a checklist rather than a single sentence: funding, sponsor role, writing support with employer and funder, per-author competing interests, data availability with a named mechanism.
- Verify the data sharing statement against the law of the relevant jurisdiction, not only against the journal’s requirements. Where consent does not support reuse, the statement should say so and give the reason.
- Consult the journal in advance on any matter the instruments leave unresolved — secondary publication in another language, recycled methods text, or a preprint already posted. A written response from an editor is decisive; an author’s own interpretation of the guidance is not.
Frequently asked questions
They are written for different readers. The ICMJE Recommendations tell authors and editors what may and may not be done: who qualifies as an author, when a second publication of the same data is acceptable, that trials must be prospectively registered and that a data sharing statement is required. COPE’s Core Practices tell journals what policies and procedures they must have, and its flowcharts tell editors how to handle an allegation of misconduct, a disputed author list or a request to retract. Authors follow ICMJE and are subject to COPE: ICMJE answers whether something may be done, and COPE answers what happens next.
Not as the governing document, but it should be consulted if there is any commercial involvement at all, such as a company supplying the study drug or devices, running the central laboratory, providing a database or funding the medical writer. GPP 2022, from DeTora and colleagues in Annals of Internal Medicine, is written for company-sponsored biomedical research, and it adds requirements that ICMJE does not impose: a written sponsor–author agreement settled before drafting, a publication plan that includes studies with unfavourable results, named disclosure of writing support, and author control of the decision to submit. For purely investigator-initiated work with no commercial input, ICMJE and the relevant reporting guideline are sufficient.
Yes: all four, by every named author. They are substantial contribution to the conception or design of the work, or to the acquisition, analysis or interpretation of data; drafting the work or critically revising it; approval of the version to be published; and agreement to be accountable for all aspects of the work, including the resolution of questions about the accuracy or integrity of any part. The cumulative structure is essential. A statistician who ran the analysis but never saw the manuscript fails criteria two and three; a department head who approved the final draft and nothing else fails criterion one. Both are acknowledged, with their contribution stated.
The sources disagree. COPE has issued text recycling guidelines that treat it as a distinct category requiring transparency rather than prohibition. Moskovitz, in Science and Engineering Ethics, argues that reusing one’s own description of an unchanged procedure is often both harmless and the clearest way to describe it. Roig’s guide for the US Office of Research Integrity takes a stricter position. In practice the journal’s own policy governs, similarity software will flag the overlap regardless, and the prudent course is to disclose the reuse in the cover letter and cite the earlier paper.
They are more common than most authors assume, although not usually fraudulent. Fang, Steen and Casadevall, in the Proceedings of the National Academy of Sciences of the USA, classified 2,047 retracted biomedical and life-science articles and found that 67.4% were retracted for misconduct (43.4% for fraud or suspected fraud, 14.2% for duplicate publication and 9.8% for plagiarism), compared with 21.3% for error. They also found that the share of articles retracted for fraud or suspected fraud had risen roughly tenfold since 1975. On authorship, Wislar and colleagues found inappropriate authorship in 21% of articles across six leading general medical journals in 2008, down from 29.1% in 1996.
The design determines the guideline, not the topic. A parallel-group randomised trial uses CONSORT 2010, from Schulz, Altman and Moher in Annals of Internal Medicine; a systematic review uses PRISMA, from Moher and colleagues in PLoS Medicine; an observational cohort, case-control or cross-sectional study uses STROBE, from von Elm and colleagues in BMJ; a single clinical case uses CARE, from Gagnier and colleagues. Extensions exist for cluster trials, non-inferiority designs, abstracts and other applications. The checklist should be used as a drafting prompt rather than a submission formality: each unmet item is a question that a reviewer would otherwise raise as a criticism.
Authors must supply the statement; whether they may lawfully share the data is a separate legal question, and the two are not fully reconciled. ICMJE has required a data sharing statement in manuscripts reporting clinical trial results since 1 July 2018, and a data sharing plan in the registration of trials enrolling from 1 January 2019. Chassang, in ecancermedicalscience, and Rumbold and Pierscionek, in the Journal of Medical Internet Research, set out the constraints the EU General Data Protection Regulation imposes; Vlahou and colleagues, in Hypertension, argue that the law and research ethics still require harmonisation. A statement that candidly explains that data cannot be shared, and why, satisfies the requirement; “available on request” without a mechanism does not.
The ICMJE Recommendations should be read once in full. The document is shorter than its reputation suggests, and it covers authorship, overlapping publication, registration, data sharing and conflicts of interest, which together account for most journal queries. The reporting guideline that matches the design used most often should then be read, and its checklist kept open while drafting rather than consulted only at submission. COPE’s Core Practices are relevant to those who edit or review, and GPP 2022 to anyone whose work is company-sponsored. These two or three documents will answer the large majority of questions that arise in practice.
References
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Text recycling guidelines. COPE. 2013. read 9 October 2026. par.nsf.gov
- International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
- Christofidou M, Arvanitis TN, Kalra D, Lea N, Shabani M, Coorevits P. Data altruism and the 'consent' question: a study into the 'consent' models used under the GDPR and how the data altruism mechanism can act as a potential solution for the research community in the reuse of health data. Frontiers in Medicine. 2025;11:1489925. doi:10.3389/fmed.2024.1489925 read 9 October 2026. doi.org/10.3389/fmed.2024.1489925
- International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
- DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
- Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, et al. Data sharing under the General Data Protection Regulation: time to harmonize law and research ethics? Hypertension. 2021;77:1029-1035. doi:10.1161/HYPERTENSIONAHA.120.16340 read 9 October 2026. doi.org/10.1161/HYPERTENSIONAHA.120.16340
- Moskovitz C. Text recycling in scientific writing. Science and Engineering Ethics. 2019;25(3):813-851. doi:10.1007/s11948-017-0008-y read 9 October 2026. doi.org/10.1007/s11948-017-0008-y
- Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, et al. CARE guidelines for case reports: explanation and elaboration document. Journal of Clinical Epidemiology. 2017;89:218-235. read 9 October 2026. community.the-hospitalist.org
- Rumbold JMM, Pierscionek BK. The effect of the General Data Protection Regulation on medical research. Journal of Medical Internet Research. 2017;19(2):e47. doi:10.2196/jmir.7108 read 9 October 2026. doi.org/10.2196/jmir.7108
- Chassang G. The impact of the EU general data protection regulation on scientific research. ecancermedicalscience. 2017;11:709. doi:10.3332/ecancer.2017.709 read 9 October 2026. doi.org/10.3332/ecancer.2017.709
- Council for International Organizations of Medical Sciences. International Ethical Guidelines for Health-related Research Involving Humans, 4th edition. CIOMS. 2016. read 9 October 2026. equator-network.org
- Roig M; US Office of Research Integrity. Avoiding plagiarism, self-plagiarism, and other questionable writing practices: a guide to ethical writing. US Office of Research Integrity. 2015. read 9 October 2026. equator-network.org
- Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
- World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194. doi:10.1001/jama.2013.281053 read 9 October 2026. doi.org/10.1001/jama.2013.281053
- Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Journal of Medical Case Reports. 2013;7(1):223. doi:10.1186/1752-1947-7-223 read 9 October 2026. doi.org/10.1186/1752-1947-7-223
- Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. Proceedings of the National Academy of Sciences of the USA. 2012;109(42):17028-17033. doi:10.1073/pnas.1212247109 read 9 October 2026. doi.org/10.1073/pnas.1212247109
- Das N, Panjabi M. Plagiarism: why is it such a big issue for medical writers? Perspectives in Clinical Research. 2011;2(2):67-71. doi:10.4103/2229-3485.80370 read 9 October 2026. doi.org/10.4103/2229-3485.80370
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
- Zhang H. CrossCheck: an effective tool for detecting plagiarism. Learned Publishing. 2010;23:9-14. read 9 October 2026. pmc.ncbi.nlm.nih.gov
- Segal S, Gelfand BJ, Hurwitz S, Berkowitz L, Ashley SW, Nadel ES, et al. Plagiarism in residency application essays. Annals of Internal Medicine. 2010;153:112-120. read 9 October 2026. pmc.ncbi.nlm.nih.gov
- Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
- Fanelli D. How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS ONE. 2009;4(5):e5738. doi:10.1371/journal.pone.0005738 read 9 October 2026. doi.org/10.1371/journal.pone.0005738
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
- Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
- Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-1812. read 9 October 2026. archive.emwa.org
- Angell M. Industry-sponsored clinical research: a broken system. JAMA. 2008;300:1069-1071. read 9 October 2026. archive.emwa.org
- Cicutto L. Plagiarism: avoiding the peril in scientific writing. Chest. 2008;133:579-581. read 9 October 2026. pmc.ncbi.nlm.nih.gov
- Arrive L, Lewin M, Dono P, Monnier-Cholley L, Hoeffel C, Tubiana JM. Redundant publication in the journal Radiology. Radiology. 2008;247:836-840. doi:10.1148/radiol.2473070969 read 9 October 2026. doi.org/10.1148/radiol.2473070969
- Titus SL, Wells JA, Rhoades LJ. Repairing research integrity. Nature. 2008;453:980-982. read 9 October 2026. archive.emwa.org
- Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine. 2008;149:251-258. read 9 October 2026. archive.emwa.org
- Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
- Durani P. Duplicate publications: redundancy in plastic surgery literature. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2006;59:975-977. read 9 October 2026. wjgnet.com
- Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
- Bilic-Zulle L, Frkovic V, Turk T, Azman J, Petrovecki M. Prevalence of plagiarism among medical students. Croatian Medical Journal. 2005;46:126-131. read 9 October 2026. pmc.ncbi.nlm.nih.gov
- von Elm E, Poglia G, Walder B, Tramer MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291(8):974-980. doi:10.1001/jama.291.8.974 read 9 October 2026. doi.org/10.1001/jama.291.8.974
- DeAngelis CD. Duplicate publication, multiple problems. JAMA. 2004;292:1745-1746. doi:10.1001/jama.292.14.1745 read 9 October 2026. doi.org/10.1001/jama.292.14.1745
- Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
- Schein M, Paladugu R. Redundant surgical publications: tip of the iceberg? Surgery. 2001;129:655-661. read 9 October 2026. wjgnet.com
- Tramer MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 1997;315:635-640. read 9 October 2026. wjgnet.com
- Kassirer JP, Angell M. Redundant publication: a reminder. New England Journal of Medicine. 1995;333:449-450. doi:10.1056/NEJM199508173330709 read 9 October 2026. doi.org/10.1056/NEJM199508173330709
- Angell M, Relman AS. Redundant publication. New England Journal of Medicine. 1989;320:1212-1214. doi:10.1056/NEJM198905043201812 read 9 October 2026. doi.org/10.1056/NEJM198905043201812
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Publication Ethics: Identifying the Instrument That Governs Each Question. Pubrica. https://pubrica.com/academy/publication-ethics/
Pubrica Academy. “Publication Ethics: Identifying the Instrument That Governs Each Question.” Pubrica, 9 Oct. 2026, pubrica.com/academy/publication-ethics/.
Pubrica Academy (2026) Publication Ethics: Identifying the Instrument That Governs Each Question. Pubrica. Available at: https://pubrica.com/academy/publication-ethics/ (Accessed: 15 October 2026).
Pubrica Academy. “Publication Ethics: Identifying the Instrument That Governs Each Question.” Pubrica. October 9, 2026. https://pubrica.com/academy/publication-ethics/
Pubrica Academy, ‘Publication Ethics: Identifying the Instrument That Governs Each Question’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/publication-ethics/> accessed 15 October 2026.
Pubrica Academy. Publication Ethics: Identifying the Instrument That Governs Each Question. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/publication-ethics/
Pubrica Academy, “Publication Ethics: Identifying the Instrument That Governs Each Question,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/publication-ethics/
@misc{publication_ethics_2026,
author = {{Pubrica Academy}},
title = {Publication Ethics: Identifying the Instrument That Governs Each Question},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/publication-ethics/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Publication-ethics routing sheet
This sheet should be completed once per manuscript, before submission. The left-hand column states the question and the right-hand column is for the answer. Any question that cannot be answered in writing is one that an editor is likely to raise.
PUBLICATION-ETHICS ROUTING SHEET
Manuscript: ______________________ Target journal: ______________________
Date: ____________ Completed by: ______________________
1. AUTHORSHIP (instrument: ICMJE Recommendations)
For each proposed author, record Y/N against all four criteria:
Name ________________ (1) contribution __ (2) drafted/revised __
(3) approved final __ (4) accountable __
Name ________________ (1) __ (2) __ (3) __ (4) __
Name ________________ (1) __ (2) __ (3) __ (4) __
[ ] Every listed author scores Y on all four
[ ] Anyone scoring N on any criterion has been moved to acknowledgements
[ ] A contributorship statement describing each person's actual role is drafted
[ ] Every named person in the acknowledgements has consented to be named
2. PRIOR PUBLICATION AND OVERLAP (instrument: ICMJE; COPE text recycling)
List every earlier public appearance of these data:
Congress abstract / poster ....... ______________________
Preprint ......................... ______________________
Registry results posting ......... ______________________
Earlier paper using same cohort .. ______________________
[ ] All of the above are disclosed in the cover letter
[ ] Any recycled text from my own earlier work is identified and the
source paper is cited
[ ] The target journal's policy on preprints and recycling has been checked
3. SPONSOR RELATIONSHIP (instrument: GPP 2022 -- only if commercial input)
Commercial involvement (funding / drug / device / lab / database / writer):
______________________________________________________
[ ] A written sponsor-author agreement exists and predates drafting
[ ] The agreement leaves the decision to submit with the authors
[ ] Writing support is disclosed by name, employer and funder
[ ] The publication plan covers unfavourable results from this programme
4. REPORTING (instrument: the EQUATOR guideline for this design)
Study design: ______________________
Guideline applied: ______________________
[ ] Checklist completed item by item, not at submission but during drafting
[ ] Primary outcome stated, single, and pre-specified
[ ] Harms reported
[ ] Registration number in the methods, where applicable
5. CONDUCT AND DATA (instruments: Helsinki; CIOMS; GDPR / national law)
Approving committee and reference: ______________________
Consent arrangements: ______________________
[ ] Data sharing statement drafted, naming WHAT, TO WHOM, FROM WHEN,
BY WHAT ROUTE, ON WHAT CONDITION
[ ] The mechanism named is lawful under the consent actually obtained
[ ] If data cannot be shared, the statement says so and says why
6. DISCLOSURE BLOCK ASSEMBLED
[ ] Funding source
[ ] Sponsor's role, itemised (design / data custody / analysis / submission)
[ ] Writing support, named
[ ] Competing interests, per author, with lookback period
[ ] Data availability
7. OPEN QUESTIONS TO PUT TO THE EDITOR BEFORE SUBMITTING
______________________________________________________
______________________________________________________ Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s publication-support team applies this routing in reverse: it reviews a manuscript, identifies the instrument under which each of its exposures falls, and drafts the authorship, disclosure and data-sharing text to the standard applied by the target journal. Where a sponsor relationship exists, the team works from GPP 2022 and the written agreement rather than from habit. Where a question is genuinely unsettled — recycled methods text, or a preprint already posted — the team states this and assists authors in obtaining a written answer from the editor before submission rather than after.